NASDAQ:GOSS Gossamer Bio (GOSS) Stock Price, News & Analysis → After Conviction, More Bad News for Trump (From Paradigm Press) (Ad) Free GOSS Stock Alerts $0.55 -0.05 (-8.36%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$0.54▼$0.6350-Day Range$0.55▼$1.2752-Week Range$0.45▼$1.88Volume1.09 million shsAverage Volume1.34 million shsMarket Capitalization$124.06 millionP/E RatioN/ADividend YieldN/APrice Target$7.65 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Gossamer Bio alerts: Email Address Gossamer Bio MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside1,295.0% Upside$7.65 Price TargetShort InterestBearish5.56% of Shares Sold ShortDividend StrengthN/ASustainability-0.67Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$39,682 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.35) to ($0.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.18 out of 5 starsMedical Sector192nd out of 905 stocksPharmaceutical Preparations Industry85th out of 430 stocks 3.4 Analyst's Opinion Consensus RatingGossamer Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageGossamer Bio has only been the subject of 3 research reports in the past 90 days.Read more about Gossamer Bio's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.56% of the outstanding shares of Gossamer Bio have been sold short.Short Interest Ratio / Days to CoverGossamer Bio has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Gossamer Bio has recently decreased by 2.10%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldGossamer Bio does not currently pay a dividend.Dividend GrowthGossamer Bio does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGossamer Bio has received a 76.36% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Gossamer Bio is -0.67. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 7 people have searched for GOSS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Gossamer Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Gossamer Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $39,682.00 in company stock.Percentage Held by InsidersOnly 5.00% of the stock of Gossamer Bio is held by insiders.Percentage Held by Institutions81.23% of the stock of Gossamer Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Gossamer Bio's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Gossamer Bio are expected to decrease in the coming year, from ($0.35) to ($0.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gossamer Bio is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gossamer Bio is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGossamer Bio has a P/B Ratio of 1.96. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Gossamer Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressAfter Conviction, More Bad News for TrumpAs a former advisor to the CIA, the Pentagon and the White House… I feel it’s my duty to warn you about this coming election meltdown.Click here to see the details because this coming election meltdown could trigger… About Gossamer Bio Stock (NASDAQ:GOSS)Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.Read More GOSS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GOSS Stock News HeadlinesMay 21, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Gossamer Bio on Seralutinib’s Promising Clinical Data and Future ProspectsMay 14, 2024 | businesswire.comGossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International ConferenceMay 10, 2024 | businesswire.comGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Gossamer Bio Amidst Strategic Collaboration and Market Opportunity GrowthMay 9, 2024 | bizjournals.comCary headquarters plays crucial role in $160 million dealMay 8, 2024 | msn.comGossamer Bio and Chiesi partner for pulmonary hypertension treatmentMay 7, 2024 | businesswire.comGossamer Bio Announces First Quarter 2024 Financial Results and Provides Business UpdateMay 7, 2024 | markets.businessinsider.comBuy Rating on Gossamer Bio Supported by Strategic Partnership and Market UnderestimationMay 6, 2024 | finance.yahoo.comUPDATE 1-Gossamer Bio and Chiesi Group to collaborate in therapy for lung conditionMay 6, 2024 | finance.yahoo.comGossamer Bio Collaborates With Italian Drugmaker Chiesi To Advance Lung Health Solutions WorldwideMay 6, 2024 | reuters.comGossamer Bio and Chiesi Group to collaborate for blood pressure treatmentMay 3, 2024 | businesswire.comGossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory MedicineMay 2, 2024 | msn.comWhat Ralph Waldo Emerson Knew About MoneyApril 26, 2024 | finance.yahoo.comGossamer Bio Decline Means Insider Profits Down To US$17kMarch 27, 2024 | markets.businessinsider.comBuy Rating Affirmed on Gossamer Bio with Promising Seralutinib Prospects in PAH Treatment LandscapeMarch 21, 2024 | investing.comGossamer Bio EVP sells over $5,000 in company stockMarch 21, 2024 | investing.comGossamer Bio executive sells over $5,000 in company stockMarch 21, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Diamedica Therapeutics (DMAC), Gossamer Bio (GOSS) and Vor Biopharma (VOR)March 16, 2024 | ca.finance.yahoo.comGOSS Apr 2024 1.500 putMarch 16, 2024 | finance.yahoo.comGOSS Apr 2024 1.000 putMarch 13, 2024 | theguardian.comTara Rae Moss: ‘So many doctors in different continents told me that I would never recover’March 12, 2024 | finance.yahoo.comGossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of DirectorsMarch 12, 2024 | businesswire.comGossamer Bio Announces Appointment of Steven D. Nathan, M.D.March 11, 2024 | markets.businessinsider.comBarclays Keeps Their Hold Rating on Gossamer Bio (GOSS)March 7, 2024 | markets.businessinsider.comOptimistic Buy Rating for Gossamer Bio Amidst Progress in PAH Treatment MarketSee More Headlines Receive GOSS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today6/07/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GOSS CUSIPN/A CIK1728117 Webwww.gossamerbio.com Phone(858) 684-1300FaxN/AEmployees135Year FoundedN/APrice Target and Rating Average Stock Price Target$7.65 High Stock Price Target$15.00 Low Stock Price Target$1.25 Potential Upside/Downside+1,295.0%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-179,820,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-525.73% Return on Assets-62.70% Debt Debt-to-Equity Ratio7.37 Current Ratio7.13 Quick Ratio7.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.28 per share Price / Book1.96Miscellaneous Outstanding Shares226,220,000Free Float214,908,000Market Cap$124.06 million OptionableOptionable Beta1.90 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesMr. Faheem Hasnain (Age 66)Co-Founder, CEO, President & Chairman Comp: $910.26kMr. Bryan Giraudo (Age 49)COO & CFO Comp: $708.09kMr. Robert P. Smith (Age 55)Chief Commercial Officer Comp: $135.79kMr. Christian Waage (Age 57)Executive Vice President of Technical Operations & Administration Comp: $583.16kMr. Jeff BoernekeGeneral Counsel & SecretaryMs. Deanna WeberSenior Vice President of Human ResourcesDr. Richard Aranda M.D. (Age 63)Chief Medical Officer Comp: $625.24kMr. Mario OrlandoSenior Vice President of Commercial New Product PlanningMs. Caryn L. Peterson (Age 65)Executive Vice President of Regulatory Affairs Mr. Matt CravetsSenior Vice President of BiometricsMore ExecutivesKey CompetitorsKalVista PharmaceuticalsNASDAQ:KALVAstria TherapeuticsNASDAQ:ATXSNeurogeneNASDAQ:NGNECryoportNASDAQ:CYRXAvid BioservicesNASDAQ:CDMOView All CompetitorsInsiders & InstitutionsJacobs Levy Equity Management Inc.Sold 468,964 shares on 5/16/2024Ownership: 0.722%Price T Rowe Associates Inc. MDSold 804,222 shares on 5/15/2024Ownership: 1.278%Platinum Investment Management Ltd.Sold 2,260,045 shares on 5/14/2024Ownership: 2.075%Vanguard Group Inc.Bought 128,150 shares on 5/10/2024Ownership: 5.200%Acadian Asset Management LLCBought 931,248 shares on 5/10/2024Ownership: 1.210%View All Insider TransactionsView All Institutional Transactions GOSS Stock Analysis - Frequently Asked Questions Should I buy or sell Gossamer Bio stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GOSS shares. View GOSS analyst ratings or view top-rated stocks. What is Gossamer Bio's stock price target for 2024? 5 brokerages have issued 1-year target prices for Gossamer Bio's shares. Their GOSS share price targets range from $1.25 to $15.00. On average, they expect the company's share price to reach $7.65 in the next year. This suggests a possible upside of 1,295.0% from the stock's current price. View analysts price targets for GOSS or view top-rated stocks among Wall Street analysts. How have GOSS shares performed in 2024? Gossamer Bio's stock was trading at $0.9125 at the start of the year. Since then, GOSS stock has decreased by 39.9% and is now trading at $0.5484. View the best growth stocks for 2024 here. When is Gossamer Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our GOSS earnings forecast. How were Gossamer Bio's earnings last quarter? Gossamer Bio, Inc. (NASDAQ:GOSS) issued its earnings results on Tuesday, May, 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.19). What other stocks do shareholders of Gossamer Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Gossamer Bio investors own include Editas Medicine (EDIT), Alector (ALEC), Sorrento Therapeutics (SRNE), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Stoke Therapeutics (STOK), Precision BioSciences (DTIL) and Invitae (NVTA). When did Gossamer Bio IPO? Gossamer Bio (GOSS) raised $230 million in an initial public offering (IPO) on Friday, February 8th 2019. The company issued 14,400,000 shares at a price of $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI acted as the underwriters for the IPO. Who are Gossamer Bio's major shareholders? Gossamer Bio's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.20%), Platinum Investment Management Ltd. (2.08%), Price T Rowe Associates Inc. MD (1.28%), Acadian Asset Management LLC (1.21%), Jacobs Levy Equity Management Inc. (0.72%) and Monaco Asset Management SAM (0.25%). Insiders that own company stock include Bryan Giraudo, Caryn Peterson, Faheem Hasnain, Laura Carter, Richard Aranda and Waage Christian. View institutional ownership trends. How do I buy shares of Gossamer Bio? Shares of GOSS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GOSS) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gossamer Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gossamer Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.